Endo Pharmaceuticals has announced
that the FDA has granted final approval for the company's new drug applications
(NDAs) for its extended-release and immediate-release formulations of oxymorphone
hydrochloride. These products are now known under the trade names Opana ER tablets
and Opana tablets.
Opana ER is indicated for the relief of moderate-to-severe
pain in patients requiring continuous, around-the-clock opioid treatment for an
extended period of time. This is the first time oxymorphone will be available
in an oral, extended-release formulation. Opana ER will be available in 5 mg,
10 mg, 20 mg and 40 mg tablets. Opana (the immediate-release version) is indicated
for the relief of moderate-to-severe acute pain where the use of an opioid is
appropriate and will be available in 5mg and 10mg tablets.
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
FDA Approves Contact Lens for Myopia in Children
The lens focus light on the back of the eye, which is believed to reduce progression of the condition.
HHS Hits Gilead With Patent Infringement Suit Over PrEP Drugs
Truvada was approved in 2012 for use as a PreP regimen, and Descovy was approved in October 2019 as a PrEP regimen.
